 NEW YORK, June 04, 2021 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the first patient had been dosed in the Phase 1b2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1PD-L1 antibody mAb and radiation therapy RT. This triple combination is actively recruiting at The University of Texas MD Anderson Cancer Center, with Dr. Vivek Subbiah as principal investigator, in seven metastatic or locally advanced cancers, which include bladder cancer, melanoma, Merkel cell cancer, MSI-H cancers of any histology, non-small cell lung cancer NSCLC, renal cell cancer, and small cell lung cancer SCLC. 